News

We are happy to see Functional Fluidics expanding to Africa and setting up a new research clinic and laboratory in Nigeria. And we are truly grateful for the significant contributions …

The Department of Health of Puerto Rico has granted authorization to market Endari, an oral powder treatment for sickle cell disease (SCD). The first FDA-backed oral glutamine, Endari has been …

Sickle cell disease affects a significant number of individuals in North Carolina, particularly within the Black community, where about 95 percent of cases are found. This genetic blood disorder not …

A recent study conducted in Uganda revealed that treatment with hydroxyurea significantly reduced the incidence of severe or invasive infections among children with sickle cell anemia by 60%. Sickle cell …

The first patient has been administered with BEAM-101 in the BEACON trial, a Phase 1/2 clinical study conducted by Beam Therapeutics for sickle cell disease (SCD). Following the transplantation, stem …

Emmaus Life Sciences has launched Endari, a medication aimed at alleviating acute complications in individuals battling sickle cell disease, now accessible via prescription across the United States. Sickle cell disease, …

In a significant move to address health disparities and enhance care for individuals with sickle cell disease (SCD) in New Jersey, Governor Phil Murphy signed legislation appropriating $10.2 million for …

CES 2024, themed “AI in Everything,” has prompted various industries to explore interdisciplinary integration, with the AI medical sector serving as a prominent example. Moderna, a pharmaceutical tech giant, has …

Bluebird bio’s CEO, Andrew Obenshain, defends the 40% premium on the list price of the gene therapy Lyfgenia compared to competitors Vertex and CRISPR Therapeutics. Obenshain highlights the outcomes-based contracts, …